Jeffrey V. Poulton

2019

In 2019, Jeffrey V. Poulton earned a total compensation of $5.9M as Executive Vice President, Chief Financial Officer principal financial officer at Alnylam Pharmaceuticals.

Compensation breakdown

Non-Equity Incentive Plan$136,740
Option Awards$5,479,525
Salary$254,808
Other$6,343
Total$5,877,416

Poulton received $5.5M in option awards, accounting for 93% of the total pay in 2019.

Poulton also received $136.7K in non-equity incentive plan, $254.8K in salary and $6.3K in other compensation.

Rankings

In 2019, Jeffrey V. Poulton's compensation ranked 1,766th out of 13,971 executives tracked by ExecPay. In other words, Poulton earned more than 87.4% of executives.

ClassificationRankingPercentile
All
1,766
out of 13,971
87th
Division
Manufacturing
627
out of 5,695
89th
Major group
Chemicals And Allied Products
187
out of 2,194
92nd
Industry group
Drugs
150
out of 1,880
92nd
Industry
Pharmaceutical Preparations
112
out of 1,392
92nd
Source: SEC filing on April 2, 2021.

Poulton's colleagues

We found five more compensation records of executives who worked with Jeffrey V. Poulton at Alnylam Pharmaceuticals in 2019.

2019

John Maraganore

Alnylam Pharmaceuticals

Chief Executive Officer

2019

Yvonne Greenstreet

Alnylam Pharmaceuticals

Chief Operating Officer

2019

Barry Greene

Alnylam Pharmaceuticals

Former President

2019

Akshay Vaishnaw

Alnylam Pharmaceuticals

President, Research and Development

2019

Laurie Keating

Alnylam Pharmaceuticals

Chief Legal Officer

News

In-depth

You may also like